합성생물학 기술 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Synthetic Biology Technology Market

The future of the global synthetic biology technology market looks promising with opportunities in the medicine, chemical, and agriculture markets. The global synthetic biology technology market is expected to reach an estimated $13.1 billion by 2035 from $3.4 billion in 2027 with a CAGR of 14.1% from 2027 to 2035. The major drivers for this market are the increasing demand for personalized medicine, the rising investments in biotechnology innovations, and the growing applications in agriculture & healthcare.

• Lucintel forecasts that, within the type category, gene synthesis is expected to witness the highest growth over the forecast period due to increased need for custom gene synthesis in scientific studies.
• Within the application category, agriculture is expected to witness the highest growth over the forecast period due to more scientific studies using synthetic biology to increase crop productivity.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to rising funding for agricultural biotechnology, and more concern for global food supply and quality.

Emerging Trends in Synthetic Biology Technology Market

As synthesize biology technologies become more established, we expect substantial growth in the period 2025-2027 as innovations in pharmaceuticals, food and chemicals integration facilitate faster time to market and positive platform economics.

• Pharmaceuticals and Bio-Design: During 2025, specialised protein foundation models and on-premises protein design simulations enabled by AI and accelerated by high-throughput computing, are expected to reduce protein design timelines from months to days.
• Biomanufacturing: The number of companies with the capability to perform precision fermentation at commercial scale increased in 2025. Similar improvements are expected to enable the production of animal-based bio-pharmaceuticals and meat. The economically viable commercial products of the next several years will be determined by the companies with the largest, best-in-class, and most-controlled biomanufacturing facilities.
• Chemicals: In 2025, several large consumer packaged goods (CPG) companies committed to using bio-based chemicals and materials to reduce the carbon footprint of their supply chains. Reducing the reliance on fossil fuels to produce chemicals is likely to drive further adoption of synthetic biology.
• Synthetic Biology Convergence: By 2025, we anticipate the integration of synthetic biology with gene editing and cell and delivery system engineering. This will result in broader therapeutic pipelines. The need for standardization of manufacturing processes and the generation of regulatory datasets will also increase.
• Regional Diversification of Production: The decentralization of fermentation and biotechnology production, observed in North America, Europe, and Asia between 2025 and 2027, is aimed at risk mitigation of overreliance on international supply. Production unit location will be strategically aligned to national interests.

The development and adoption of synthetic biology will increasingly hinge on the restraint demonstrated by the field's pioneers in scaling their platforms and on the enabling role of regulatory agencies. Growth in the synthetic biology space will primarily be realized in the production of pharmaceuticals, with further potential opportunities in the production of chemicals and materials. Progress in the field is expected to benefit sustainability. Integration of design-merch software to facilitate the production of targeted biomolecules will be advantageous. From a business perspective, it will be prudent to evaluate the sustainability of a company's platforms and integrate permanent solutions to meet the rising regulatory requirements.

Recent Developments in the Synthetic Biology Technology Market

Investor sentiment shifted from platform companies to product companies in the synthetic biology space in the 2025 investment cycle. It is expected that between 2025 and 2027, the industry will focus on incorporating AI in biomanufacturing and product design, as well as the launch of biomedical products in the regulated market. According to Lucintel, speculative synthetic biology programs will continue to decline, and significant collaborations will increase.

• Strategic Collaboration: In January 2025, Ginkgo Bioworks entered into a collaboration with Merck to combine Merck's cell- and gene-editing technology and programs with Ginkgo's cell programming platform. The collaboration was expected to generate infrastructure and design programs for biomedical products.
• Product Expansion: In 2025, CJ CheilJedang announced a plan to build a large-scale plant in the U.S. to manufacture amino acids, which are building blocks of proteins. The company also announced a plan to build a large-scale plant in the U.S. to manufacture other specialty ingredients. With the new U.S. based manufacturing capacity, synthetic biology companies will have a local source to manufacture products at commercial scales.
• Government Approval: The European Commission endorsed the recommendations of the Critical Medicines Alliance in March 2025. The recommendations promoted on-shore production of medicines in Europe. Synthetic biology will play a role in producing medicines in Europe and other regions if national security is threatened due to dependence on other countries to produce the pharmaceutical inputs.
• Investment Announcement: In 2025, the U.S. Department of Energy awarded more than $200 million in funding to organizations in the field of Industrial Biotechnology. Funding at this stage enables companies to build commercial-scale processing facilities and helps to prepare the market for large-scale bio-based products.
• Product Announcement: In May 2025, Microsoft and Ginkgo Bioworks announced an integration of cloud computing and laboratory automation to produce the first automated biological engineering platform. As with other computer-assisted design (CAD) tools, this platform is expected to reduce the cost and increase the speed of biological engineering.

In the near and medium term, the most newsworthy events for companies in this space are anticipated to be customer contracts, production scale-up and regulatory breakthroughs. During the same time period, it is expected that biological engineering companies will be acquired by larger companies and that platform companies will be acquired by investment funds. These events are expected to occur especially in the field of synthetic biology where companies utilize biological organisms to replace petrochemical and animal-based products.

Strategic Growth Opportunities in the Synthetic Biology Technology Market

The affordable cost of synthesizing genes coupled with the improved capacity of biomanufacturing systems is enabling the movement of the synthetic biology industry from laboratory-based R&D to product development and commercialization. The emphasis on the development of more resilient and sustainable supply chains, as well as the use of less complex and faster methods for the development of pharmaceuticals, will create specific, high-demand markets from 2024 to 2026. During this period, Lucintel expects it will be advantageous for companies to invest in companies that develop technologies in these markets rather than to invest in companies that develop broad-based platforms.

• Pharmaceuticals: The use of synthetic biology in the development of pharmaceuticals has rapidly expanded to include the treatment of cancer and autoimmune disorders and is expected to accelerate further with the development of other vaccines. The FDA's Biologics Evaluation process has approved 6 cell and gene therapies since January 2025.
• Chemicals: The use of organisms to manufacture polymers and other chemical and pharmaceutical products is expected to displace the use of petrochemicals. The European Union has set a goal of deriving at least 42.5% of its energy from renewable sources by 2030.
• Digital Manufacturing: The rise of automatic design, build, test, and learn systems means contract developers and manufacturers can charge for services previously provided at no cost. In February 2025, numerous users of cloud-based development systems reported 30% or greater cycle time reduction. In the next 3 to 5 years, competing integrators of data will allow users to customize developments. During this period, scalable systems will be differentiators in the market.
• Geographic Expansion: The United States has enacted policies to establish biomanufacturing facilities, but these policies do not offer the same level of incentives as other countries. In June 2025, India's BioE3 policy established a target of 100 biomanufacturing facilities by 2030. First movers in the market with training, consulting, and other allied services will find opportunities in South Asia and the Middle East.
• Aftermarket Services: Recurring revenue from after-sales services is expected from platforms sold for bioprocessing. In August 2025, the bioprocessing industry reported 20% of fermentation processes remained "broken" and required remediation. Service contracts will gain popularity. The shift from pilot to commercial batches will increase the value of remediation services.

Biomanufacturing companies that can integrate strains, processes and supplies for various applications will be able to generate the highest margins. companies will be able to enter and quickly commercialize their products through partnerships with manufacturers and distributors. Focus on execution will help overcome challenges associated with large-scale production of biopharmaceuticals. The above trends are expected to continue.

Synthetic Biology Technology Market Drivers and Challenges

There are numerous factors affecting the synthetic biology technology market, including the rate of technological progress, the level of interest from industry, the investment climate, the balance of sustainability and biosecurity concerns, and changing regulations. While cost reduction in automation and genetic sequencing increases access to the technologies, the unstable economy and concerns regarding biosecurity decrease the vitality of the market. According to Lucintel, the future of the market will depend on the integration of the necessary infrastructural, policy, and regulatory frameworks. It will help translate advances made in laboratory science into commercial offerings.

The factors responsible for driving this market include:

• Customer Demand: Sustainability concerns have promoted the development of biologically derived ('green') alternatives to chemistry and materials (e.g. medicines, chemicals, plastics, foams, etc.) traditionally sourced from petroleum. Synthetic biological systems have the potential to provide greater control over product attributes and manufacturing processes, including the potential to lower the environmental impact of products. Between 2022 and 2025, growing public awareness about the environmental impact of industrial activities, along with the attainment of the UN Sustainable Development Goals and national-level sustainability goals, is projected to advance the market for green (bio)chemical, biological, and materials systems. There will also be increasing demand for bio-based materials and systems to produce food and other consumer goods, and to support the production of medicines.
• Improvements in Biotechnology: More accurate and faster tools in synthetic biology allow design and fabrication of biological systems in a similar way that computer-aided design and manufacturing (CAD/CAM) tools changed engineering. In January 2025, many fully automated labs consisted of up to 10 consecutive modules for design, construction, and testing, as well as data analysis. In the next years, even more integrated and automated systems will allow improved control and process management in biological production, and will shorten time required for transfer of research organisms to large-scale production.
• Regulatory Frameworks: Also, frameworks for biotechnology, gene editing, bio-based manufacturing and other advanced technologies for production of food and other products have been developed by many countries. Positive trends in these strategies promoted domestic biomanufacturing and enhanced security of supply chains in biotechnology. Established regulatory and standards bodies have improved certainty of biotech regulations, and harmonized standards and risk frameworks encouraged investment and market entry. It is expected, that in the next 5 years, these policies and funding will facilitate market development and accelerate commercialization of advanced biotechnology products.
• Sustainability Priorities: Companies have begun to utilize genetically engineered microorganisms and cells as part of their efforts to decrease emissions and meet their climate goals. Industrial biotechnology projects have set targets to reduce the intensity of energy and carbon emissions and increase waste productivity by 20% compared to traditional methods. In the coming years, advances in synthetic biology will likely be found in applications such as the production of renewable and biodegradable materials and surface coatings. Funding and investment opportunities, such as government grants, will also reward the achievement of established sustainability goals. The trend is expected to increase the use of biologically produced materials.
• Manufacturing Priorities: Innovations in biotechnology have improved the production of high-value compounds by using approaches from the pharmaceutical and chemical industries. Increased yields and reduced batch-to-batch variability have been achieved by using cell lines with genetically engineered pathways. In April 2025, the final step in the production of pharmaceutical compounds was performed in large bioreactors. The adoption of modular bioreactor systems enabled the easy and rapid installation of large-scale production capacity to meet market demand. The same flexibility will be required to meet variable demand for a range of products.

The challenges facing this market include:

• High Commercialization Costs: Synthetic biology is a rapidly developing field, which increases the expense of breaking through barriers to commercialize products. As of June 2025, biomanufacturing processes typically took five or more years to advance from laboratory proof-of-concept to large-scale manufacturing. In the next five years, substantial financial sponsorship will be required to build commercial scale biomanufacturing facilities. Depending on the rate that unit economics improve, some projects may become unfunded.
• Regulatory and Biosecurity Challenges: Synthetic biology products have the potential for trans-border movement and variation in regulation. Additionally, there are increased concerns about the potential for accidental release and misuse. Synthetic biology products will require multiple layers of regulation. In the next five years, a lack of harmonization among regulations may prohibit international commerce. The synthetic biology field is ripe for promoting positive changes for society and the economy, but unnecessary obstacles for governance may constrain positive progress.
• Scale Up and Supply Chain Limitations: There can be a gap between what is produced in the laboratory and what can be produced on a large scale in an industrial setting. This is especially true when the components of the biological system being produced are not standardized and if there are limitations in access to specialized equipment, personnel, and technologies. As of August 2025, many biomanufacturing projects still relied on fewer than 10 contract organizations for pilot-scale production. It is expected that lack of adequate facilities, equipment, and personnel will disrupt and extend the time needed to bring a biologically produced system to market. Investment and partnerships to establish biomanufacturing facilities in different regions will enhance and speed up the commercialization of biomanufacturing.

There are many favorable conditions to drive the commercialization of the synthetic biology market. For example, more strict environmental and sustainability regulations, automation in the production of biochemical systems, regional and national policies to support and encourage the commercial production of biologically engineered systems, and advancements in biomanufacturing and biosecurity are all factors that are expected to strengthen and support the Synthetic Biology market. Challenges including costly and lengthy processes to produce large-scale biologically produced systems will be offset by advances in the market. Companies that are best positioned in these areas will thrive. It is anticipated that within the next five years, advancements in biosafety and affordable biomanufacturing will lead to the commercialization of numerous biological systems.

List of Synthetic Biology Technology Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies synthetic biology technology market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the synthetic biology technology market companies profiled in this report include-

• GenScript
• Thermo Fisher Scientific
• IDT
• Eurofins Genomics
• DNA 2.0
• BBI
• Azenta Life Sciences
• SBS Genetech
• Bio Basic
• Twist Bioscience

Synthetic Biology Technology Market by Segment

The study includes a forecast for the global synthetic biology technology market by type, application, and region.

Synthetic Biology Technology Market by Type [Value ($B) from 2019 to 2035]:

• Gene Synthesis
• Oligonucleotide Synthesis
• Bioinformatics Analysis
• DNA Assembly

Synthetic Biology Technology Market by Application [Value ($B) from 2019 to 2035]:

• Medicine
• Chemical
• Agriculture
• Others

Synthetic Biology Technology Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Synthetic Biology Technology Market

There has been an increasing number of partnerships, public research investments, and incentive biomanufacturing investments, and as a result, the scope of synthetic biology has broadened. Public policy and capacity are most closely aligned in the timeframe of 2025 to 2027. During this period, strategically engineered biology is integrated across various sectors, including pharmaceuticals, chemicals, food, and supply chains.

• United States: Continued investment by Federal Agencies to advance Biomanufacturing and Biosecurity led companies to increase investments and expand biomanufacturing capabilities. In January 2025, the Department of Defense awarded four biomanufacturing contracts worth a total of $32.9 million. Continued investment and research by Federal Agencies will increase domestic biomanufacturing capabilities and reduce reliance on other countries for biomanufacturer products within the next three to five years.
• China: Strategic Emerging Industries (2025 Plan) and National Innovation (2020 Plan) simultaneously advance biomanufacturing. Further, the coordination of Policy and Industry clustering speeds up the commercialization of new products and services.
• Germany: The EU approved Germany's €2.6 billion climate-neutral industry fund in February 2025. The fund will support the development of biotech and bio-based manufacturing industries. Germany, one of the largest manufacturers in the world, has been struggling to maintain high-value manufacturing, primarily due to high energy costs. With this support, Germany is expected to improve the competitiveness of bio-based manufacturing.
• India: The BioE3 policy of the Department of Biotechnology has been supporting the establishment of biomanufacturing facilities and biofoundries. The 2025 Union Budget of India allocated ₹100 billion for a research fund to stimulate industry to undertake research and innovation. These initiatives are expected to promote synergies between advanced biology and biotech with large scale industrial production.
• Japan: Funds available through the 2025 economic security and innovation programs of Japan supported biotech. The programs, combined with the focus on fermentation-derived materials, will encourage the development of other high-value, manufacturing intensive processes and products.

Features of the Global Synthetic Biology Technology Market

• Market Size Estimates: synthetic biology technology market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: synthetic biology technology market size by type, application, and region in terms of value ($B).
• Regional Analysis: synthetic biology technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the synthetic biology technology market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the synthetic biology technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the synthetic biology technology market by type (gene synthesis, oligonucleotide synthesis, bioinformatics analysis, and DNA assembly), application (medicine, chemical, agriculture, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Synthetic Biology Technology Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Gene Synthesis : Trends and Forecast 2019 to 2035
• 4.4 Oligonucleotide Synthesis : Trends and Forecast 2019 to 2035
• 4.5 Bioinformatics Analysis : Trends and Forecast 2019 to 2035
• 4.6 DNA Assembly : Trends and Forecast 2019 to 2035

5. Global Synthetic Biology Technology Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Medicine : Trends and Forecast 2019 to 2035
• 5.4 Chemical : Trends and Forecast 2019 to 2035
• 5.5 Agriculture : Trends and Forecast 2019 to 2035
• 5.6 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Synthetic Biology Technology Market by Region

7. North American Synthetic Biology Technology Market

• 7.1 Overview
• 7.2 North American Synthetic Biology Technology Market by Type
• 7.3 North American Synthetic Biology Technology Market by Application
• 7.4 The United States Synthetic Biology Technology Market
• 7.5 Canadian Synthetic Biology Technology Market
• 7.6 Mexican Synthetic Biology Technology Market

8. European Synthetic Biology Technology Market

• 8.1 Overview
• 8.2 European Synthetic Biology Technology Market by Type
• 8.3 European Synthetic Biology Technology Market by Application
• 8.4 German Synthetic Biology Technology Market
• 8.5 French Synthetic Biology Technology Market
• 8.6 Italian Synthetic Biology Technology Market
• 8.7 Spanish Synthetic Biology Technology Market
• 8.8 The United Kingdom Synthetic Biology Technology Market

9. APAC Synthetic Biology Technology Market

• 9.1 Overview
• 9.2 APAC Synthetic Biology Technology Market by Type
• 9.3 APAC Synthetic Biology Technology Market by Application
• 9.4 Chinese Synthetic Biology Technology Market
• 9.5 Indian Synthetic Biology Technology Market
• 9.6 Japanese Synthetic Biology Technology Market
• 9.7 South Korean Synthetic Biology Technology Market
• 9.8 Indonesian Synthetic Biology Technology Market

10. ROW Synthetic Biology Technology Market

• 10.1 Overview
• 10.2 ROW Synthetic Biology Technology Market by Type
• 10.3 ROW Synthetic Biology Technology Market by Application
• 10.4 Middle Eastern Synthetic Biology Technology Market
• 10.5 South American Synthetic Biology Technology Market
• 10.6 African Synthetic Biology Technology Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Synthetic Biology Technology Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 GeneScript
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Thermo Fisher Scientific
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 IDT
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Eurofins Genomics
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 DNA 2.0
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BBI
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Azenta Life Sciences
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 SBS Genetech
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Bio Basic
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Twist Bioscience
  • Company Overview
  • Synthetic Biology Technology Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us